NCT02486133View on ClinicalTrials.gov

Dual Therapy With Boosted Darunavir + Dolutegravir

PHASE3CompletedINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
HIV-Infection
Interventions
DRUG

Prezista

once daily

DRUG

Norvir

once daily

DRUG

Tivicay

once daily

DRUG

Truvada

once daily

DRUG

Kivexa

once daily

DRUG

Descovy

once daily

Trial Locations (1)

81675

Klinikum rechts der Isar, Munich

All Listed Sponsors
lead

Technical University of Munich

OTHER

NCT02486133 - Dual Therapy With Boosted Darunavir + Dolutegravir | Biotech Hunter | Biotech Hunter